ReviewDiabetes, obesity & metabolism2020

Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme.

Tina K Thethi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.